ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Renal Transplant Patient Outcomes Following Plasmapheresis, Thymoglobulin, and Rituximab Induction for High Risk DSA Positive Recipients.

E. Lessmann,1 M. Moaddab,1 M. Manson,1 A. Ram,2 R. Kerman,2 P. Jindra.2

1Pharmacy, CHI St. Luke's Health Baylor St. Luke's Medical Center, Houston, TX
2Immune Evaluation Laboratory, Baylor College of Medicine, Houston, TX

Meeting: 2017 American Transplant Congress

Abstract number: B176

Keywords: HLA antibodies, Induction therapy, Kidney transplantation

Session Information

Session Name: Poster Session B: Kidney Immunosuppression: Induction Therapy

Session Type: Poster Session

Date: Sunday, April 30, 2017

Session Time: 6:00pm-7:00pm

 Presentation Time: 6:00pm-7:00pm

Location: Hall D1

Background: Kidney transplantation is associated with improved survival and quality of life relative to dialysis for patients with end-stage renal disease (ESRD). Patients who are highly human leukocyte antigen (HLA)-sensitized are among the most vulnerable populations awaiting kidney transplantation. The recent UNOS organ allocation policy change has enhanced access to transplantation for patients who are highly sensitized. At our institution, we have implemented guidelines for the management of donor specific antibody (DSA) positive patients which includes plasmapheresis, thymoglobulin, and rituximab induction. The purpose of this study was to assess our DSA protocol on sensitized patient outcomes.

Methods: This was a single center, retrospective data review of 150 patients who underwent kidney transplantation at our center between January 2014 and June 2016.

Results: Of the kidney transplants performed, 34.7% (52/150) received the DSA protocol. Of patients receiving the DSA protocol, 5 were virtual crossmatch (XM) and 3 flow B cell XM positive. All were flow T cell XM and cytotoxic XM negative. Recipients averaged a class I PRA of 51% and 36% for class II. Donor specific anti-HLA antibodies had an average class I MFI of 2773 and class II MFI of 4417. Overall, 16.7% (25/150) of recipients had biopsy proven rejection. Of the recipients who received the DSA protocol, 15.4% had biopsy proven rejection with the majority (62.5%) diagnosed with acute cellular rejection (ACR), 25% of recipients had a combined ACR and antibody mediated rejection (AMR), and 12.5% had AMR alone. Stable serum creatinine (SCr) was observed in both the DSA positive group with a median SCr at 6 months 1.52 (IQR 1.25-1.83) and 1 year 2.21 (IQR 1.35-2.79) and DSA negative group with a median SCr at 6 months 1.57 (IQR 1.12-1.91) and 1 year 1.59 (IQR 1.36-1.96). Of the 5 patients that suffered graft loss, 1 was in the DSA positive group and also experienced one documented episode of ACR.

Conclusion: These data suggest induction with plasmapheresis, thymoglobulin and rituximab leads to superior outcomes in sensitized patients with low level anti-HLA antibodies. Based on our induction protocol and maintenance immunosuppression strategy, having low level anti-HLA antibodies should not be a contraindication to transplant.

CITATION INFORMATION: Lessmann E, Moaddab M, Manson M, Ram A, Kerman R, Jindra P. Renal Transplant Patient Outcomes Following Plasmapheresis, Thymoglobulin, and Rituximab Induction for High Risk DSA Positive Recipients. Am J Transplant. 2017;17 (suppl 3).

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

To cite this abstract in AMA style:

Lessmann E, Moaddab M, Manson M, Ram A, Kerman R, Jindra P. Renal Transplant Patient Outcomes Following Plasmapheresis, Thymoglobulin, and Rituximab Induction for High Risk DSA Positive Recipients. [abstract]. Am J Transplant. 2017; 17 (suppl 3). https://atcmeetingabstracts.com/abstract/renal-transplant-patient-outcomes-following-plasmapheresis-thymoglobulin-and-rituximab-induction-for-high-risk-dsa-positive-recipients/. Accessed June 1, 2025.

« Back to 2017 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences